September looms as a risk month for stocks, Yardeni says
LEXINGTON, MA - Keros Therapeutics, Inc. (NASDAQ:KROS), a biopharmaceutical company, announced today that it has successfully completed the enrollment of its Phase 2 clinical trial, named TROPOS, which is evaluating the efficacy of cibotercept (KER-012) in combination with background therapy for patients with pulmonary arterial hypertension (PAH).
The trial has enrolled a total of 113 patients, surpassing the initial target of 90 participants.
The company, headquartered in Lexington, Massachusetts, stated that the topline data from the TROPOS trial is anticipated to be presented in the second quarter of 2025.
This information was disclosed in a filing with the Securities and Exchange Commission (SEC) on Monday.
In other recent news, Keros Therapeutics has been receiving positive attention from Guggenheim, particularly due to the company's promising drug candidates. The firm has given a 'Buy' rating to the biotech company, setting a price target at $96. This favorable outlook is driven by Keros's potential for treating a range of diseases, with a special focus on hematology.
Guggenheim highlighted elritercept, a drug being investigated for the treatment of myelodysplastic syndromes and myelofibrosis, as commercially viable programs. The firm's optimism is further bolstered by the prospects of another Keros drug candidate, cibotercept, for the treatment of pulmonary arterial hypertension (PAH).
InvestingPro Insights
Keros Therapeutics' recent announcement about completing enrollment for its Phase 2 TROPOS trial aligns with its focus on developing treatments for hematological and musculoskeletal disorders. While the company shows promise in its clinical trials, InvestingPro data reveals some financial challenges. As of the last twelve months ending Q2 2024, Keros reported a revenue of just $0.27 million USD, with a significant gross profit margin of -55,400.37%. This indicates that the company is still in its early stages and heavily investing in research and development.
InvestingPro Tips highlight that Keros holds more cash than debt on its balance sheet, which is crucial for a biotech company in the development phase. Additionally, the company has shown a strong return over the last year, with a 77.07% price total return. These factors suggest that despite current losses, investors remain optimistic about Keros' potential.
It's worth noting that analysts anticipate a sales decline in the current year and do not expect the company to be profitable this year. This aligns with the nature of biotech companies investing heavily in clinical trials before generating significant revenue.
For investors interested in a deeper analysis, InvestingPro offers 11 additional tips for Keros Therapeutics, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.